Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28437307 | 0.98 | MEN1 (0.48) | MEN1KMT2ATSHRSMN1; SMN2CXCR4 | |
| SCHEMBL31465622 | 0.95 | MEN1 (0.48) | MEN1KMT2ATSHRSMN1; SMN2CXCR4 | |
| SCHEMBL9293161 | 0.93 | PAOX (0.49) | MEN1KMT2ATSHRSMN1; SMN2CXCR4 | |
| Hydrochloric Acid SCHEMBL18263836 | 0.92 | PAOX (0.47) | MEN1KMT2ATSHRSMN1; SMN2CXCR4 | |
| Hydrochloric Acid SCHEMBL9462599 | 0.92 | PAOX (0.47) | MEN1KMT2ATSHRSMN1; SMN2CXCR4 | |
| SCHEMBL6603043 | 0.89 | SMN1; SMN2 (0.56) | MEN1KMT2ATSHRSMN1; SMN2HRH2 | |
| Hydrochloric Acid SCHEMBL4114140 | 0.87 | SMN1; SMN2 (0.54) | MEN1KMT2ATSHRSMN1; SMN2HRH2 | |
| Hydrochloric Acid SCHEMBL8480707 | 0.87 | SMN1; SMN2 (0.54) | MEN1KMT2ATSHRSMN1; SMN2HRH2 | |
| SCHEMBL5856730 | 0.87 | SMN1; SMN2 (0.43) | MEN1KMT2ATSHRSMN1; SMN2HRH2 | |
| SCHEMBL11570934 | 0.87 | TSHR (0.58) | TSHRSMN1; SMN2GLAALDH1A1PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119405832-A | Splice modulating antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119405833-A | Splice modulating antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119405831-A | Splice modulating antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119405834-A | Splice modulating antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119233964-A | Single component delivery system for nucleic acids | 宾夕法尼亚大学理事会 | 2024-12-31 | — | — | CN | disclosed |
| CN-112218663-B | Splice modulating antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | disclosed |
| EP-4347550-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | The Trustees of the University of Pennsylvania (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251191-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-5908843-A | Piperazine compounds as fibrinogen inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-06-01 | — | — | US | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5776937-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-07-07 | — | — | US | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0711770-A1 | Antagonists of adhesion receptors | MERCK PATENT GmbH (DE) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | TLR3, TLR9, ADAR | MEN1 1712/4885KMT2A 1037/4885TSHR 2174/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | MEN1 1064/4885KMT2A 1096/4885TSHR 3167/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | MEN1 474/4885KMT2A 2404/4885TSHR 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.